A Prospective, Randomized, Controlled Trial of Methylene Blue Injection for Costal Cartilage Harvest Postoperative Analgesia

What Was Tested

Researchers studied Methylene blue (non-peptide stack partner) in this randomized controlled trial publication.

In plastic surgery, costal cartilage is an excellent support material.

However, postoperative pain from costal cartilage harvesting can impact patient recovery and satisfaction with the surgery.

Who Took Part

According to the abstract, 106 patients were involved.

PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.

A total of 106 patients undergoing costal cartilage harvesting surgery were selected from the plastic surgery department between December 2022 and March 2024.

They were randomly divided into 2 groups: the MB group and the ropivacaine group, with 53 patients in each group.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Methylene blue (non-peptide stack partner) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Pain levels were assessed with a numerical rating scale, the Insomnia Severity Index (ISI), arm elevation angle, and postoperative satisfaction scales at 1 day, 3 days, 5 days, 1 week, 1 month, and 3 months postoperatively.

What Was Measured

PubMed files the paper under topics including Methylene Blue, Postoperative Pain, Ropivacaine, Pain Measurement, Patient Satisfaction, Costal Cartilage and Tissue and Organ Harvesting.

What This Means in Plain Language

The paper is a randomized study of Methylene blue (non-peptide stack partner) in 106 patients.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Aesthetic surgery journal), a journal based in England.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.